<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRANXENE T-TAB- clorazepate dipotassium tablet </strong><br>RECORDATI RARE DISEASES, INC.<br></p></div>
<h1>Tranxene* T-TAB<span class="Sup">®</span> Tablets C-IV/DEA Schedule IV       <br>(clorazepate dipotassium tablets, USP)<br><br>R<span class="Sub">x</span> only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION</h1>
<p class="First">Chemically, TRANXENE is a benzodiazepine.  The empirical formula is C<span class="Sub">16</span>H<span class="Sub">11</span>C<span class="Sub">l</span>K<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">4</span>; the molecular weight is 408.92; 1<span class="Italics">H</span>-1, 4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt compound with potassium hydroxide (1:1) and the structural formula may be represented as follows:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=structuralFormula.jpg"></div>
<p>The compound occurs as a fine, light yellow, practically odorless powder. It is insoluble in the common organic solvents, but very soluble in water. Aqueous solutions are unstable, clear, light yellow, and alkaline.</p>
<p>TRANXENE T-TAB tablets contain either 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium for oral administration.</p>
<p>Inactive ingredients for TRANXENE T-TAB Tablets: Colloidal silicon dioxide, FD&amp;C Blue No. 2 (3.75 mg only), FD&amp;C Yellow No. 6 (7.5 mg only), FD&amp;C Red No. 3 (15 mg only), magnesium oxide, magnesium stearate, microcrystalline cellulose, potassium carbonate, potassium chloride, and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY</h1>
<p class="First">Pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. The serum half-life is about 2 days. The drug is metabolized in the liver and excreted primarily in the urine.</p>
<p>Studies in healthy men have shown that clorazepate dipotassium has depressant effects on the central nervous system. Prolonged administration of single daily doses as high as 120 mg was without toxic effects. Abrupt cessation of high doses was followed in some patients by <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, or <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>.</p>
<p>Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours. Plasma levels of nordiazepam increase proportionally with TRANXENE dose and show moderate accumulation with repeated administration. The protein binding of nordiazepam in plasma is high (97-98%).</p>
<p>Within 10 days after oral administration of a 15 mg (50 μ Ci) dose of <span class="Sup">14</span>C-TRANXENE to two volunteers, 62-67% of the radioactivity was excreted in the urine and 15-19% was eliminated in the feces. Both subjects were still excreting measurable amounts of radioactivity in the urine (about 1% of the <span class="Sup">14</span>C-dose) on day ten.</p>
<p>Nordiazepam is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE</h1>
<p class="First">TRANXENE is indicated for the management of <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> or for the short-term relief of the symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with the stress of everyday life usually does not require treatment with an anxiolytic.</p>
<p>TRANXENE tablets are indicated as adjunctive therapy in the management of <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span>.</p>
<p>The effectiveness of TRANXENE tablets in long-term management of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient.</p>
<p>TRANXENE tablets are indicated for the symptomatic relief of acute alcohol withdrawal.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS</h1>
<p class="First">TRANXENE tablets are contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug and in those with acute narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-5.1"></a><p></p>
<h2>Use in Depressive Neuroses or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reactions</span>:</h2>
<p class="First">TRANXENE tablets are not recommended for use in depressive neuroses or in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-5.2"></a><p></p>
<h2>Use in Children:</h2>
<p class="First">Because of the lack of sufficient clinical experience, TRANXENE tablets are not recommended for use in patients less than 9 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-5.3"></a><p></p>
<h2>Interference with Psychomotor Performance:</h2>
<p class="First">Patients taking TRANXENE tablets should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating dangerous machinery including motor vehicles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-5.4"></a><p></p>
<h2>Concomitant Use with CNS Depressants:</h2>
<p class="First">Since TRANXENE has a central nervous system depressant effect, patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.   </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-5.5"></a><p></p>
<h2>Physical and Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</h2>
<p class="First">Withdrawal symptoms (similar in character to those noted with barbiturates and alcohol) have occurred following abrupt discontinuance of clorazepate. Withdrawal symptoms associated with the abrupt discontinuation of benzodiazepines have included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation of clorazepate should generally be avoided and a gradual dosage tapering schedule followed.</p>
<p>Caution should be observed in patients who are considered to have a psychological potential for <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span>.</p>
<p>Evidence of <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> has been observed in dogs and rabbits which was characterized by <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span> when the drug was abruptly withdrawn or the dose was reduced; the syndrome in dogs could be abolished by administration of clorazepate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation:</h2>
<p class="First">Antiepileptic drugs (AEDs), including TRANXENE, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. <a href="#SPLSERV-67DA56FE-0D2A-DDDB-54A5-668F5B0A662E">Table 1</a> shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a name="SPLSERV-67DA56FE-0D2A-DDDB-54A5-668F5B0A662E"></a><table width="80%">
<caption><span>Table 1: Risk by indication for antiepileptic drugs in the pooled analysis</span></caption>
<colgroup>
<col align="left" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">Indication</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Placebo Patients with Events Per 1000 Patients</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Drug Patients with Events Per 1000 Patients</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Risk Difference: Additional Drug Patients with Events Per 1000 Patients</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td class="Botrule Lrule Rrule" align="center">1.0</td>
<td class="Botrule Lrule Rrule" align="center">3.4</td>
<td class="Botrule Lrule Rrule" align="center">3.5</td>
<td class="Botrule Lrule Rrule" align="center">2.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Psychiatric</td>
<td class="Botrule Lrule Rrule" align="center">5.7</td>
<td class="Botrule Lrule Rrule" align="center">8.5</td>
<td class="Botrule Lrule Rrule" align="center">1.5</td>
<td class="Botrule Lrule Rrule" align="center">2.9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Other</td>
<td class="Botrule Lrule Rrule" align="center">1.0</td>
<td class="Botrule Lrule Rrule" align="center">1.8</td>
<td class="Botrule Lrule Rrule" align="center">1.9</td>
<td class="Botrule Lrule Rrule" align="center">0.9</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Total</td>
<td class="Botrule Lrule Rrule" align="center">2.4</td>
<td class="Botrule Lrule Rrule" align="center">4.3</td>
<td class="Botrule Lrule Rrule" align="center">1.8</td>
<td class="Botrule Lrule Rrule" align="center">1.9</td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<p>Anyone considering prescribing TRANXENE or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-5.7"></a><p></p>
<h2>Usage in Pregnancy:</h2>
<p class="First">An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Clorazepate dipotassium, a benzodiazepine derivative, has not been studied adequately to determine whether it, too, may be associated with an increased risk of fetal abnormality. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug.</p>
<p>To provide information regarding the effects of <span class="Italics">in utero </span>exposure to TRANXENE, physicians are advised to recommend that pregnant patients taking TRANXENE enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website <span class="Underline">http://www.aedpregnancyregistry.org/</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-5.8"></a><p></p>
<h2>Usage during Lactation:</h2>
<p class="First">TRANXENE tablets should not be given to nursing mothers since it has been reported that nordiazepam is excreted in human breast milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS</h1>
<p class="First">In those patients in which a degree of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> accompanies the <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, suicidal tendencies may be present and protective measures may be required. The least amount of drug that is feasible should be available to the patient. </p>
<p>Patients taking TRANXENE tablets for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> should have blood counts and liver function tests periodically. The usual precautions in treating patients with impaired renal or hepatic function should also be observed. </p>
<p>In elderly or debilitated patients, the initial dose should be small, and increments should be made gradually, in accordance with the response of the patient, to preclude <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> or excessive sedation.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.1"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, it is essential that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.</p>
<p>Patients, their caregivers, and families should be counseled that AEDs, including TRANXENE, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
<p>Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 (see <span class="Underline"><span class="Bold"><a href="#splSectionPrecautionsPregnancy">Usage in Pregnancy</a></span></span>).</p>
<p>Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with clorazepate dipotassium and should counsel them in its appropriate use. A patient Medication Guide is available for TRANXENE. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is available at www.recordatirarediseases.com.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-6.2"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">See<span class="Bold"><span class="Underline"><span class="Bold"></span><a href="#splSectionWarnings">WARNINGS</a></span>.</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-6.3"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of TRANXENE were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects. Elderly or debilitated patients may be especially sensitive to the effects of all benzodiazepines, including Tranxene. In general, elderly or debilitated patients should be started on lower doses of Tranxene and observed closely, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy. Dose adjustments should also be made slowly, and with more caution in this patient population (see <span class="Underline"><span class="Bold"><a href="#splSectionPrecautions">PRECAUTIONS</a></span></span> and <span class="Underline"><span class="Bold"><a href="#splSectionDosageAdministration">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-7"></a><p></p>
<h1>
ADVERSE REACTIONS</h1>
<p class="First">The side effect most frequently reported was <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Less commonly reported (in descending order of occurrence) were: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, various gastrointestinal complaints, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>. Other side effects included <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, transient <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, genitourinary complaints, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>.</p>
<p>There have been reports of abnormal liver and kidney function tests and of decrease in hematocrit.</p>
<p>Decrease in systolic blood pressure has been observed.</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-8"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-8.1"></a><p></p>
<h2>For the symptomatic relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>:</h2>
<p class="First">TRANXENE T-TAB tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.</p>
<p>TRANXENE tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> may occur at the initiation of treatment and with dosage increment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-8.2"></a><p></p>
<h2>For the symptomatic relief of acute alcohol withdrawal:</h2>
<p class="First">The following dosage schedule is recommended:</p>
<table cellpadding="4" width="60%">
<colgroup>
<col align="left" width="40%">
<col align="center" width="60%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">1st 24 hours (Day 1)</td>
<td class="Botrule Lrule Rrule Toprule" align="left">30 mg initially; followed by 30 to 60 mg in divided doses</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">2nd 24 hours (Day 2)</td>
<td class="Botrule Lrule Rrule" align="left">45 to 90 mg in divided doses</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">3rd 24 hours (Day 3)</td>
<td class="Botrule Lrule Rrule" align="left">22.5 to 45 mg in divided doses</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Day 4</td>
<td class="Botrule Lrule Rrule" align="left">15 to 30 mg in divided doses</td>
</tr>
</tbody>
</table>
<p>Thereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient’s condition is stable.</p>
<p>The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-8.3"></a><p></p>
<h2>As an Adjunct to Antiepileptic Drugs:</h2>
<p class="First">In order to minimize <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, the recommended initial dosages and dosage increments should not be exceeded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-8.4"></a><p></p>
<h2>Adults:</h2>
<p class="First">The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-8.5"></a><p></p>
<h2>Children (9-12 years):</h2>
<p class="First">The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-9"></a><p></p>
<h1>
DRUG INTERACTIONS</h1>
<p class="First">If TRANXENE is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition. Clinical studies have shown increased sedation with concurrent hypnotic medications. The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.</p>
<p>If TRANXENE tablets are used to treat <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication.</p>
<p>In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-10"></a><p></p>
<h1>
OVERDOSAGE</h1>
<p class="First">Overdosage is usually manifested by varying degrees of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> ranging from slight sedation to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.</p>
<p>The treatment of overdosage should consist of the general measures employed in the management of overdosage of any CNS depressant. Gastric evacuation either by the induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, lavage, or both, should be performed immediately. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, though rarely reported, may occur with large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>. In such cases the use of agents such as norepinephrine bitartrate injection, USP or metaraminol bitartrate injection, USP should be considered.</p>
<p>While reports indicate that individuals have survived <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of clorazepate dipotassium as high as 450 to 675 mg, these doses are not necessarily an accurate indication of the amount of drug absorbed since the time interval between ingestion and the institution of treatment was not always known. Sedation in varying degrees was the most common physiological manifestation of clorazepate dipotassium overdosage. Deep <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> when it occurred was usually associated with the ingestion of other drugs in addition to clorazepate dipotassium.</p>
<p>Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients treated with flumazenil should be monitored for resedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and other residual benzodiazepine effects for an appropriate period after treatment.<span class="Bold"> The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span> The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should be consulted prior to use.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="splSectionAnimalPharm"></a><a name="section-11"></a><p></p>
<h1>
ANIMAL PHARMACOLOGY AND TOXICOLOGY</h1>
<p class="First">Studies in rats and monkeys have shown a substantial difference between doses producing tranquilizing, sedative and toxic effects. In rats, conditioned avoidance response was inhibited at an oral dose of 10 mg/kg; sedation was induced at 32 mg/kg; the LD<span class="Sub">50</span> was 1320 mg/kg. In monkeys <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> was reduced at an oral dose of 0.25 mg/kg; sedation (<span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>) was induced at 7.5 mg/kg; the LD<span class="Sub">50</span> could not be determined because of the emetic effect of large doses, but the LD<span class="Sub">50</span> exceeds 1600 mg/kg.</p>
<p>Twenty-four dogs were given clorazepate dipotassium orally in a 22-month toxicity study; doses up to 75 mg/kg were given. Drug-related changes occurred in the liver; weight was increased and <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> with minimal <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> was found, but lobular architecture remained well preserved.</p>
<p>Eighteen rhesus monkeys were given oral doses of clorazepate dipotassium from 3 to 36 mg/kg daily for 52 weeks. All treated animals remained similar to control animals. Although total leucocyte count remained within normal limits it tended to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in the female animals on the highest doses.</p>
<p>Examination of all organs revealed no alterations attributable to clorazepate dipotassium. There was no damage to liver function or structure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-11.1"></a><p></p>
<h2>Reproduction Studies:</h2>
<p class="First">Standard fertility, reproduction, and teratology studies were conducted in rats and rabbits. Oral doses in rats up to 150 mg/kg and in rabbits up to 15 mg/kg produced no abnormalities in the fetuses. TRANXENE did not alter the fertility indices or reproductive capacity of adult animals. As expected, the sedative effect of high doses interfered with care of the young by their mothers (see <span class="Underline"><span class="Bold"><a href="#splSectionPrecautionsPregnancy">Usage in Pregnancy</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-12"></a><p></p>
<h1>
HOW SUPPLIED</h1>
<p class="First">TRANXENE 3.75 mg scored T-TAB tablets are supplied as blue-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 31:</p>
<p>Bottles of 100 (NDC 55292-301-01).</p>
<div class="Figure"><img alt="
tranxene-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=tranxene-02.jpg"></div>
<p>7.5 mg scored T-TAB tablets are supplied as peach-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 32:</p>
<p>Bottles of 100 (NDC 55292-302-01).</p>
<div class="Figure"><img alt="
tranxene-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=tranxene-03.jpg"></div>
<p>15 mg scored T-TAB tablets are supplied as lavender-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 33:</p>
<p>Bottles of 100 (NDC 55292-303-01).</p>
<div class="Figure"><img alt="
tranxene-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=tranxene-04.jpg"></div>
<p>Recommended storage: Protect from moisture. Keep bottle tightly closed. Store at 20-25°C (68-77°F). See USP controlled room temperature. Dispense in a USP tight, light-resistant container.</p>
<p>T-TAB tablet appearance and shape are registered trademarks of Recordati Rare Diseases Inc.</p>
<p>U.S. Design Pat. No. D-300,879</p>
<p>Manufactured by: AbbVie LTD, Barceloneta, PR 00617</p>
<p>For: Recordati Rare Diseases Inc., Lebanon, NJ 08833, U.S.A.</p>
<p><span class="Bold">RECORDATI RARE DISEASES GROUP</span></p>
<p>* Trademark of Sanofi-Aventis <br>® Trademark of Recordati Rare Diseases Inc.</p>
<p>Revised: February 2013</p>
<p>03-A771-R6</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="splSectionMedguide"></a><a name="section-13"></a><p></p>
<h1>
MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Tranxene* (TRAN-zeen) T-TAB<span class="Sup">®</span></span><br><span class="Bold">(clorazepate dipotassium)</span><br><span class="Bold">tablets</span><br><span class="Bold">C-IV/DEA Schedule IV</span></p>
<p>Read this Medication Guide before you start taking TRANXENE and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. </p>
<p><br><span class="Bold">What is the most important information I should know about TRANXENE?</span></p>
<p><span class="Bold">Do not stop taking TRANXENE without first talking to your healthcare provider.  </span></p>
<p>Stopping TRANXENE suddenly can cause serious problems.  </p>
<p><span class="Bold">TRANXENE can cause serious side effects, including: </span></p>
<p><span class="Bold">1.  TRANXENE can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or dizzy and can slow your thinking and motor skills</span></p>
<ul class="Disc">
<li>Do not drive, operate heavy machinery, or do other dangerous activities until you know how TRANXENE affects you.</li>
<li>Do not drink alcohol or take other drugs that may make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or dizzy while taking TRANXENE without first talking to your healthcare provider.  When taken with alcohol or drugs that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, TRANXENE may make your <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> much worse.</li>
</ul>
<p><span class="Bold">2.  TRANXENE can cause abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</span></p>
<ul class="Disc"><li>Do not stop taking TRANXENE all of a sudden. Stopping TRANXENE suddenly can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that do not stop, hearing or seeing things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, and stomach and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>.<dl>
<dt>-</dt>
<dd>Talk to your doctor about slowly stopping TRANXENE to avoid getting sick with withdrawal symptoms.</dd>
<dt>-</dt>
<dd>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is not the same as <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>. Your healthcare provider can tell you more about the differences between physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>.</dd>
</dl>
</li></ul>
<p><span class="Bold">TRANXENE is a federally controlled substance (C-IV) because it can be abused or lead to <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Keep TRANXENE in a safe place to prevent misuse and abuse. Selling or giving away TRANXENE may harm others, and is against the law. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines or street drugs.</span></p>
<p><span class="Bold">3.  TRANXENE may harm your unborn or developing baby.</span></p>
<p>Medicines like TRANXENE can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Talk with your healthcare provider if you are pregnant or plan to become pregnant. Tell your healthcare provider right away if you become pregnant while taking TRANXENE. You and your healthcare provider should decide if you will take TRANXENE while you are pregnant. <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> may occur even in children born to women who are not taking any medicines and do not have other risk factors.</p>
<ul class="Disc">
<li>If you become pregnant while taking TRANXENE, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can register by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.</li>
<li>Tranxene can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take TRANXENE. You and your healthcare provider should decide if you will take TRANXENE or breast feed. You should not do both.</li>
</ul>
<p><span class="Bold">4.  Like other antiepileptic drugs, TRANXENE may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.</span></p>
<p><span class="Bold">Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<ul class="Disc">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions?</span></p>
<ul class="Disc">
<li>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.</li>
</ul>
<p>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.</p>
<p><span class="Bold">Do not stop TRANXENE without first talking to a healthcare provider.</span></p>
<p>Stopping <span class="Bold">TRANXENE</span> suddenly can cause serious problems.</p>
<p>Stopping a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine suddenly in a patient who has <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that will not stop (<span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>). </p>
<p>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.</p>
<p><br><span class="Bold">What is TRANXENE?</span></p>
<p>TRANXENE is a prescription medicine used: </p>
<ul class="Disc">
<li>to treat <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> </li>
<li>with other medicines to treat <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> </li>
<li>to treat the symptoms of sudden alcohol withdrawal</li>
</ul>
<p><br><span class="Bold">Who should not take TRANXENE?</span></p>
<p>Do not take TRANXENE if you:</p>
<ul class="Disc">
<li>are allergic to clorazepate dipotassium or any of the ingredients in TRANXENE. See the end of this Medication Guide for a complete list of ingredients in TRANXENE. </li>
<li>have an eye disease called acute narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</li>
</ul>
<p><br><span class="Bold">What should I tell my healthcare provider before taking TRANXENE?</span></p>
<p><span class="Bold">Before you take TRANXENE, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have liver or kidney problems</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems, or suicidal thoughts or behavior</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior (<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span>)</li>
<li>have any other medical conditions </li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements.   Taking TRANXENE with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.</p>
<p>Know the medicines you take.  Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. </p>
<p><br><span class="Bold">How should I take TRANXENE?</span></p>
<ul class="Disc">
<li>Take TRANXENE exactly as prescribed.  Your healthcare provider will tell you how much TRANXENE to take. </li>
<li>Your healthcare provider may change your dose.  Do not change your dose of TRANXENE without talking to your healthcare provider.  </li>
<li>Do not stop taking TRANXENE without first talking to your healthcare provider. Stopping TRANXENE suddenly can cause serious problems. </li>
</ul>
<p>If you take too much TRANXENE, call your healthcare provider or local Poison Control Center right away. </p>
<p><br><span class="Bold">What are the possible side effects of TRANXENE?</span></p>
<p>See <span class="Bold">"What is the most important information I should know about TRANXENE?"</span></p>
<p>The most common side effects of TRANXENE include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </li>
</ul>
<p>These are not all the possible side effects of TRANXENE.  For more information ask your healthcare provider or pharmacist.  </p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.  </p>
<p><span class="Bold">Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><br><span class="Bold">How should I store TRANXENE?</span></p>
<ul class="Disc">
<li>Store TRANXENE between 68°F to 77°F (20°C to 25°C).</li>
<li>Keep TRANXENE in a tightly closed container.  </li>
<li>Keep TRANXENE out of the light.</li>
<li>Keep TRANXENE tablets dry. </li>
</ul>
<p><span class="Bold">Keep TRANXENE and all medicines away from children.</span></p>
<p><br><span class="Bold">General Information about TRANXENE</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRANXENE for a condition for which it was not prescribed. Do not give TRANXENE to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Medication Guide summarizes the most important information about TRANXENE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about TRANXENE that is written for health professionals.</p>
<p>For more information about TRANXENE, go to www.recordatirarediseases.com or call Recordati Rare Diseases Inc. at 1-888-575-8344.</p>
<p><br><span class="Bold">What are the ingredients in TRANXENE?</span></p>
<p>Active ingredient: clorazepate dipotassium</p>
<p>Inactive ingredients: colloidal silicon dioxide, magnesium oxide, magnesium stearate, microcrystalline cellulose, potassium carbonate, potassium chloride and talc.</p>
<p>In addition:</p>
<ul class="Disc">
<li>the 3.75 mg tablets contain FD&amp;C Blue No. 2</li>
<li>the 7.5 mg tablets contain FD&amp;C Yellow No. 6</li>
<li>the 15 mg tablets contain FD&amp;C Red No. 3</li>
</ul>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by: AbbVie LTD, Barceloneta, PR 00617</p>
<p>For: Recordati Rare Diseases Inc., Lebanon, NJ 08833, U.S.A.</p>
<p><span class="Bold"> RECORDATI RARE DISEASES GROUP</span></p>
<p>* Trademark of Sanofi-Aventis <br>® Trademark of Recordati Rare Diseases Inc.</p>
<p>Revised: February 2013 <br><br>03-A771-R6</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-14"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC </span>55292-301-01 <br><br><span class="Bold">100 Tablets<br><br>Tranxene* T-Tab<span class="Sup">®</span> Tablets<br>(clorazepate dipotassium tablets, USP)<br><br>3.75 mg CIV<br><br>DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT. GO TO www.recordatirarediseases.com<br><br>Rx</span> only <br><span class="Bold"><br>RECORDATI RARE DISEASES GROUP<br><br></span>Each tablet contains 3.75 mg clorazepate dipotassium.<br><br>See package insert for full prescribing information.<br><br>Store at 20-25ºC (68-77ºF). See USP controlled room temperature.<br><br>Protect from moisture. Keep bottle tightly closed.<br><br>Dispense in a USP tight, light-resistant container.<br><br>Do not accept if seal over bottle opening is broken or missing.<br><br>Manufactured by: <br>AbbVie LTD <br>Barceloneta, PR 00617 <br><br>For: Recordati Rare Diseases Inc. <br>Lebanon, NJ 08833, U.S.A.<br><br>Exp. <br><br>Lot <br><br>04-B185-R6 (4389)</p>
<div class="Figure"><img alt="3.75 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=3-75mg.jpg"></div>
<p><span class="Bold">NDC </span>55292-302-01 <br><br><span class="Bold">100 Tablets<br><br>Tranxene* T-Tab<span class="Sup">®</span> Tablets<br>(clorazepate dipotassium tablets, USP)<br><br>7.5 mg CIV<br><br>DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT. GO TO www.recordatirarediseases.com<br><br>Rx </span>only <br><span class="Bold"><br>RECORDATI RARE DISEASES GROUP<br><br></span>Each tablet contains 7.5 mg clorazepate dipotassium.<br><br>See package insert for full prescribing information.<br><br>Store at 20-25ºC (68-77ºF). See USP controlled room temperature.<br><br>Protect from moisture. Keep bottle tightly closed.<br><br>Dispense in a USP tight, light-resistant container.<br><br>Do not accept if seal over bottle opening is broken or missing.<br><br>Manufactured by: <br>AbbVie LTD <br>Barceloneta, PR 00617 <br><br>For: Recordati Rare Diseases Inc. <br>Lebanon, NJ 08833, U.S.A.<br><br>Exp. <br><br>Lot <br><br>04-B186-R6 (4390)</p>
<div class="Figure"><img alt="7.5 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=7-5mg.jpg"></div>
<p><span class="Bold">NDC </span>55292-303-01 <br><br><span class="Bold">100 Tablets<br><br>Tranxene* T-Tab<span class="Sup">®</span> Tablets<br>(clorazepate dipotassium tablets, USP)<br><br>15 mg CIV<br><br>DISPENSE THE ENCLOSED MEDICATION GUIDE TO EACH PATIENT. GO TO www.recordatirarediseases.com<br><br>Rx </span>only <br><span class="Bold"><br>RECORDATI RARE DISEASES GROUP<br><br></span>Each tablet contains 15 mg clorazepate dipotassium.<br><br>See package insert for full prescribing information.<br><br>Store at 20-25ºC (68-77ºF). See USP controlled room temperature.<br><br>Protect from moisture. Keep bottle tightly closed.<br><br>Dispense in a USP tight, light-resistant container.<br><br>Do not accept if seal over bottle opening is broken or missing.<br><br>Manufactured by: <br>AbbVie LTD <br>Barceloneta, PR 00617 <br><br>For: Recordati Rare Diseases Inc. <br>Lebanon, NJ 08833, U.S.A.<br><br>Exp. <br><br>Lot <br><br>04-B187-R6 (4391)</p>
<div class="Figure"><img alt="15 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28&amp;name=15mg.jpg"></div>
<p>  </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANXENE 		
					T-TAB</strong><br><span class="contentTableReg">clorazepate dipotassium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55292-301</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLORAZEPATE DIPOTASSIUM</strong> (CLORAZEPIC ACID) </td>
<td class="formItem">CLORAZEPATE DIPOTASSIUM</td>
<td class="formItem">3.75 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (FREEFORM) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T;OV;31</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55292-301-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017105</td>
<td class="formItem">06/23/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANXENE 		
					T-TAB</strong><br><span class="contentTableReg">clorazepate dipotassium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55292-302</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLORAZEPATE DIPOTASSIUM</strong> (CLORAZEPIC ACID) </td>
<td class="formItem">CLORAZEPATE DIPOTASSIUM</td>
<td class="formItem">7.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (ORANGE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (FREEFORM) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T;OV;32</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55292-302-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017105</td>
<td class="formItem">06/23/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRANXENE 		
					T-TAB</strong><br><span class="contentTableReg">clorazepate dipotassium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55292-303</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLORAZEPATE DIPOTASSIUM</strong> (CLORAZEPIC ACID) </td>
<td class="formItem">CLORAZEPATE DIPOTASSIUM</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (PURPLE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (FREEFORM) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T;OV;33</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55292-303-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017105</td>
<td class="formItem">06/23/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>RECORDATI RARE DISEASES, INC.
							(181699406)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AbbVie LTD</td>
<td class="formItem"></td>
<td class="formItem">078521897</td>
<td class="formItem">MANUFACTURE(55292-301, 55292-302, 55292-303)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bd19117f-faca-e901-9b77-16934d81f754</div>
<div>Set id: 9c7ab45c-7461-6e4e-ee6d-f0ebe3eb4a28</div>
<div>Version: 1</div>
<div>Effective Time: 20130202</div>
</div>
</div> <div class="DistributorName">RECORDATI RARE DISEASES, INC.</div></p>
</body></html>
